TuHURA Biosciences, Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a HURA research report →
Price Chart
About the company
TuHURA Biosciences, Inc. is an immuno-oncology firm that has reached the critical Phase 3 registration stage of clinical development. The company is dedicated to pioneering innovative technologies designed to effectively combat the mechanisms by which cancers develop resistance to existing immunotherapy treatments.
- CEO
- James A. Bianco
- IPO
- 2013
- Employees
- 22
- HQ
- Tampa, FL, US
Get TickerSpark's AI analysis on HURA
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $141.38M
- P/E
- -4.11
- Fwd P/E
- 222.00
- PEG
- -0.04
- P/S
- 0.00
- P/B
- 7.68
- EV/EBITDA
- -4.79
- Div Yield
- 0.00%
- Gross Margin
- 0.00%
- Op Margin
- 0.00%
- Net Margin
- 0.00%
- ROE
- -154.32%
- ROIC
- -137.40%
Latest fiscal year · YoY change
- Revenue
- $0+0.0%
- Gross Profit
- $0+0.0%
- Op Income
- $-31,795,939
- Net Income
- $-30,060,333-38.6%
- EPS
- $-0.63+47.9%
- OCF Growth
- -87.6%
- FCF Growth
- -87.4%
- 52W High
- $3.43
- 52W Low
- $0.41
- 50D MA
- $2.27
- 200D MA
- $1.83
- Beta
- -0.01
- RSI (14)
- 49
- Avg Volume
- 471.22K
No earnings-call transcripts are available for HURA yet.
- Free Float
- 62.3%
- Shares Outstanding
- 63.68M
- Float Shares
- 39.66M
of shares held by institutions
64 13F filers
Buy/sell ratio 0.00. Sells can include pre-scheduled 10b5-1 plan sales, not just discretionary selling.
Congressional trading
Senate and House stock disclosures for HURA, newest first.
Source: public STOCK Act disclosures. Filed weeks after the trade — a lagging signal, not a real-time one.
Top institutional holders
Largest 13F positions, with quarter-over-quarter change.
| Holder | Shares | Δ Quarter |
|---|---|---|
| Vanguard Group Inc | 2.32M | ▲ 50.10K |
| Cwm, LLC | 41.76K | ▲ 40.65K |
| Journey Strategic Wealth LLC | 10.87K | ▲ 856 |
| California State Teachers Retirement System | 550 | ▼ 1.48K |
| Sunbelt Securities, Inc. | 22 | ▲ 22 |
Held by 26 ETFs
Biggest fund positions in HURA by dollar value.
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| May 28, 26 | Bianco James A. | other | 150,000 |
| Feb 12, 26 | Tendler Craig | other | 156,240 |
| Feb 12, 26 | Ng George K | other | 156,240 |
| Feb 12, 26 | MANUSO JAMES S J | other | 156,240 |
| Feb 12, 26 | List Alan | other | 156,240 |
| Feb 12, 26 | Hoffman Robert E. | other | 156,240 |
| Jan 6, 26 | Dearborn Dan | other | 273,696 |
| Jan 6, 26 | Bianco James A. | other | 610,332 |
| Dec 12, 25 | Dearborn Dan | other | 1,531,367 |
| Dec 12, 25 | Bianco James A. | other | 3,414,891 |
A “Sell” may be a pre-scheduled 10b5-1 plan sale rather than a discretionary decision — read insider selling with that in mind.
Our HURA coverage
Recent articles, reports, and earnings notes.
No research on HURA yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate HURA report →TuHURA Biosciences, Inc. (HURA) Shareholder/Analyst Call Prepared Remarks Transcript
seekingalpha.com · Aug 18
TuHURA Biosciences Highlights Phase III IFx Push, AML Trial Plans at Canaccord
marketbeat.com · Aug 14
TuHURA Biosciences Reports Second Quarter 2026 Financial Results and Provides a Corporate Update
prnewswire.com · Aug 14
TuHURA Biosciences to Present at Canaccord Genuity's 46th Annual Growth Conference
prnewswire.com · Jul 22
TuHURA Biosciences Files Investigational New Drug Application for Evaluation of the TBS-2025 VISTA Inhibiting Antibody in Molecularly Defined Subsets of AML and Other Blood Related Cancers
prnewswire.com · Jun 15
TuHURA Biosciences Reports First Quarter 2026 Financial Results and Provides a Corporate Update
prnewswire.com · May 15
TuHURA Biosciences to Present at the 4th Annual H.C. Wainwright BioConnect Investor Conference
prnewswire.com · May 12
TuHURA Biosciences Announces $50 Million Credit Facility and Royalty Transaction Extending Anticipated Cash Runway into 2028
prnewswire.com · Apr 22
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.